Navigation Links
Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers

the scientific literature that seemed to play a role in prostate cancer. They tested their expression on paraffin-embedded tumor samples taken from 71 patients, as well as on 41 control samples (non-cancerous prostate tissue taken from the same group of patients).

From this, they identified 16 candidate genes to further analyze. Ten of the genes were positively correlated to cancer progression, and six were negatively correlated, she said, and when tested, the combination generated a gene expression score that provided a better predictor of relapse than the Gleason score. "This gene expression score appears to give us additional prognostic information that current technology cannot provide, and that will help us treat patients accordingly," she said.

The assay they used was developed by Illumina Inc., of San Diego, which also funded this study. It uses fine optic beads and needs only tiny amount of DNA and RNA, Wang-Rodriguez said, and up to 96 different tests can be put on a single tray. "Having batches of samples together in a single assay that can then be read automatically makes it easy for routine clinical use," she said. "The test has a lot of potential, but needs to be further studied and validated."

Methylation Markers Are an Independent Predictor of Prostate Cancer Prognosis in a Cohort of 605 Radical Prostatectomy Patients: Abstract No. LB-226

Researchers have found that a test checking the methylation of a single gene can predict recurrence of prostate cancer in patients who have had their glands surgically removed.

In a clinical study of tumor tissue taken from 605 prostate cancer patients, those who had a positive PITX2 methylation test were three times more likely to experience cancer recurrence than those who tested negative, according to the study's lead author, Susan Cottrell, Ph.D., senior scientist at Epigenomics, Inc., in Seattle. Furthermore, the test predicted recurrence in all patient subgroups,
'"/>

Source:American Association for Cancer Research


Page: 1 2 3 4 5 6 7

Related biology news :

1. Silence the gene, save the cell: RNA interference as promising therapy for ALS
2. Exercise training in ordinary people affects the activity of 500 genes
3. New bioinformatics technique for systematically analyzing key regions in DNA that help control gene activity
4. Natural compound from pond scum shows potential activity against Alzheimers
5. Brain activity related to processing faces is similar in people with, without autism
6. Molecule by molecule, new assay shows real-time gene activity
7. Inflammation and drugs to control this activity studied in a variety of tumors sites
8. Hopkins researchers develop new tool to watch real-time chemical activity in cells
9. Structure determined for p53 tumor suppressor protein as bound to DNA for anti-cancer activity
10. Stem cell activity deciphered in the aging brain
11. Innovative movies show real-time immune-cell activity within tumors
Post Your Comments:
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a new study, Dartmouth researchers describe the structure of a ... Vibrio cholerae , the bacteria that causes cholera. Buried within ... that appears to inhibit ToxT, which prevents the bacteria from ... threatening, and, according to the World Health Organization, cholera remains ...
... In fact, toe running is far more efficient than landing ... distance endurance running, humans are some of the best-adapted animals ... why have we stuck with our inefficient heel first footfall ... marathon running? This paradox puzzled Nadja Schilling and Christoph Anders ...
... Scientists have pinpointed specific mutations that allow a common ... in the March issue of the Journal of General ... viruses and hosts could provide insight to how some viruses ... a better idea of how animal diseases are generated. ...
Cached Biology News:Dartmouth researchers describe how the cholera bacteria becomes infectious 2Human use heel first gait because it is efficient for walking 2The genetic secrets to jumping the species barrier 2
(Date:7/24/2015)... 24, 2015 Equity Research Institute ... Inc. (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ... Northwest Biotherapeutics Inc. (NASDAQ: NWBO ), and Acorda ... on PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI ... ended at 5,146.41, down 0.49%, the Dow Jones Industrial ...
(Date:7/24/2015)... DIEGO , July 24, 2015 Orexigen ... and financial results for the second quarter 2015 on ... announcement, Orexigen will provide a business update and discuss ... call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... by phone by calling (800) 447-0521 (domestic) or (847) ...
(Date:7/24/2015)... The global next generation ... billion by 2022, growing at an estimated CAGR of ... study by Grand View Research, Inc. Development of faster, ... in significant reduction in cost of sequencing one base ... rates of next generation sequencing throughout the forecast period. ...
(Date:7/24/2015)... ... July 24, 2015 , ... ... management solution, indispensable to any modern scientific or pharmaceutical laboratory. FreezerPro® is ... interface. Users know precisely where a sample is located even before opening ...
Breaking Biology Technology:Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4
... RIVER, N.Y., June 20, 2011 ... provider of software and services for health and ... 4.2 electronic health record (EHR) software for behavioral ... ARRA Ambulatory Certification. (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO) ...
... VICTORIA, Australia, June 20, 2011 Genetic Technologies Limited ... North American division, Phenogen Sciences Inc., has launched the ... risk.   Phenogen Sciences will target its ... US metro-markets.  The company has deployed its sales force ...
... ,Graphene, a one-atom-thick layer of graphitic carbon, has the ... But its unique properties, and the shrinking scale of ... produce on a large scale. In ... had overcome some of these difficulties and were able ...
Cached Biology Technology:CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 2CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 3CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 4Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
TNF-R2 (L-20)...
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
Highly sensive assay for detecting apoptosis in living cells. See detailed descriptions above in K250-25....
Eliminate electrical interference from any analog signal, without filtering. Ideal for electrophysiology applications like EKG, EMG, and EEGs. Removes 50/60hz noise and harmonics caused by grounding ...
Biology Products: